Prevalence of Hemoglobinopathies Associated With Significant Hb Variants in the Chattogram Region of Bangladesh

Hemoglobinopathies represent a collection of genetic conditions that influence the structure or synthesis of haemoglobin, the protein found in red blood cells that facilitates oxygen transport from the lungs throughout the body. This research proposal presents a study evaluating the prevalence of hemoglobinopathies and their significant haemoglobin variants within a specific population. The research will employ a cross-sectional study design, recruiting participants through community outreach efforts and healthcare facilities while obtaining informed consent. Data will be collected with the utmost precision and rigor, using advanced screening techniques such as high-performance liquid chromatography (HPLC), capillary electrophoresis, and molecular analysis. The gathered data will be processed to assess haematological parameters, including RBC, Iron Ferritin, TIBC, electrophoresis profiles (HbA, HbA2, HbE, HbF), MCV, MCHC, and PCV among individuals with hemoglobinopathies (HbE disease/trait, Beta thalassemia disease/trait, heterozygous HPFH, HbE-beta thal). They will examine variations relative to demographic factors. The expected results will have substantial clinical and public health consequences by enhancing genetic counselling, informing clinical decision-making, and strengthening public health initiatives.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hemoglobinopathies Anemia Anemia, Hemolytic Anemia, Hemolytic, Congenital Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Hematologic Diseases Hemic and Lymphatic Diseases Thalassemia beta-Thalassemia

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Science and Technology Chittagong (USTC)

Khulshi, Chattogram, 4203, Bangladesh

About this study

Hemoglobinopathies are genetic disorders affecting the structure or production of hemoglobin, the oxygen-carrying protein in red blood cells. This study aims to determine the prevalence and major variants of hemoglobinopathies in a target population using a cross-sectional design. Participants will be recruited through community outreach and healthcare facilities with informed consent. Screening will involve advanced techniques such as HPLC, capillary electrophoresis, and molecular analysis, alongside hematological assessments (RBC, ferritin, TIBC, MCV, MCHC, PCV, and hemoglobin profiles: HbA, HbA2, HbE, HbF). Findings will be analyzed in relation to demographic factors.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Residents of the Chattogram metropolitan area.
All ages and both sexes with informed consent.
Willing to provide venous blood samples.
No blood transfusion in the past 3 months.

Exclusion criteria

Refusal or withdrawal of consent.
Blood transfusion within the last 3 months.
Pregnant women.
Inadequate or hemolyzed blood samples.

Treatment and study plan

Primary outcomes

Detection of Hemoglobin Variants by Hb-Electrophoresis

Time frame: Day 1, at enrollment

Performed to detect hemoglobin variants (e.g., HbA, HbE, HbS, HbC, HbD, HbF). The outcome will report the number and percentage of participants with each variant.

Secondary outcomes

Correlation of Hematological Parameters with Demographic Factors

Time frame: Day 1, upon enrollment

Statistical correlation between hematological indices and demographic factors (eg. age, sex, family history).

Sponsors and collaborators

Lead sponsor

Bangladesh Bioscience Research Group

Network

Registry information

Official study title

Prevalence of Hb Variants and Haemoglobinopathies in a Tertiary Care Hospital: A Retrospective Cross-sectional Study

Acronym: Hb variants

Important dates

Study start: 2023
Primary completion: 2025
Study completion: 2025
First posted: Oct 6, 2025
Registry last updated: Oct 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed